0000000000504499

AUTHOR

Wang Y

showing 7 related works from this author

First Measurement of the Absolute Branching Fraction of Λ→pμ−ν¯μ

2021

The absolute branching fraction of Λ→pμ−ν¯μ is reported for the first time based on an e+e− annihilation sample of 10×109 J/ψ events collected with the BESIII detector at s=3.097 GeV. The branching fraction is determined to be B(Λ→pμ−ν¯μ)=[1.48±0.21(stat)±0.08(syst)]×10−4, which is improved by about 30% in precision over the previous indirect measurements. Combining this result with the world average of B(Λ→pe−ν¯e), we obtain the ratio {[Γ(Λ→pμ−ν¯μ)]/[Γ(Λ→pe−ν¯e)]} to be 0.178±0.028, which agrees with the standard model prediction assuming lepton flavor universality. The asymmetry of the branching fractions of Λ→pμ−ν¯μ and Λ¯→p¯μ+νμ is also determined, and no evidence for CP violation is fo…

PhysicsMeasurementAnnihilationBranching010308 nuclear & particles physicsBranching fractionmedia_common.quotation_subjectGeneral Physics and AstronomyAbsoluteTime based01 natural sciencesAsymmetryNOStandard ModelSubatomär fysikSubatomic Physics0103 physical sciencesCP violationAtomic physics010306 general physicsLeptonmedia_commonPhysical Review Letters
researchProduct

Complete Measurement of the Λ Electromagnetic Form Factors.

2019

The exclusive process e+e−→ΛΛ¯, with Λ→pπ− and Λ¯→p¯π+, has been studied at s=2.396 GeV for measurement of the timelike Λ electric and magnetic form factors, GE and GM. A data sample, corresponding to an integrated luminosity of 66.9 pb−1, was collected with the BESIII detector for this purpose. A multidimensional analysis with a complete decomposition of the spin structure of the reaction enables a determination of the modulus of the ratio R=|GE/GM| and, for the first time for any baryon, the relative phase ΔΦ=ΦE−ΦM. The resulting values are R=0.96±0.14(stat)±0.02(syst) and ΔΦ=37°±12°(stat)±6°(syst), respectively. These are obtained using the recently established and most precise value of …

Multi-dimensional analysisElectron–positron annihilationRelative phaseHadronAnalytical chemistryGeneral Physics and AstronomyHadronsOBSERVABLESLambdaBaryon01 natural sciencesArticleNOHigh Energy Physics - ExperimentSubatomär fysikGermanium compoundsElectromagnetic form factorsSubatomic Physics0103 physical sciencesMagnetic form factorTwo-photon exchangePiddc:530010306 general physicsAsymmetry parameterProton Scattering; Nucleons; HydrogenPhysicsIntegrated luminosityDecompositionPhysicsHigh Energy Physics::PhenomenologyApproximation theoryPhysics multidisciplinaryPhotonHigh Energy Physics - Experiment; High Energy Physics - ExperimentBaryonLuminanceSpin structuresHigh Energy Physics::ExperimentMagnetic form factorMulti dimensional analysisBar (unit)Physical review letters
researchProduct

Carga global, regional y nacional de neurológicas. Desórdenes, 1990-2016: un análisis sistemático para el Global Estudio de la carga de enfermedad 20…

2019

Publisher´s version (útgefin grein).

DánarmeinMaleEpidemiologyDiseasesMalalties cerebralsGlobal Burden of DiseaseDisability Evaluation0302 clinical medicineCase fatality ratePsychologyKonurCause of deathAged 80 and overeducation.field_of_studyIncidenceMenTaugavísindiddc:3. Good healthSálfræðiWorld healthMuerteNeurologyGBD 2016 Neurology CollaboratorsBrain diseasesQuality-Adjusted Life YearsAlzheimer diseaseCarga global de enfermedadesNervous systemmedicine.medical_specialtyGlobal burden of diseasesLífsgæðiArticle03 medical and health sciencesHealth SciencesHumansWomeneducationTrastornos neurológicosVLAGAgedScience & Technology3112 NeurosciencesGlobal Burden of Diseases030104 developmental biologyYears of potential life lostΕπιστήμες ΥγείαςDementiaHuman medicineNeurosciences & NeurologyNeurology (clinical)Clinical Medicine1109 NeurosciencesNeurological disorders030217 neurology & neurosurgerydementiaRC0301 basic medicinePediatricsDánartíðniNutrition and Disease3124 Neurology and psychiatryDisease StudyTaugasjúkdómarRisk FactorsVoeding en ZiekteCause of DeathGlobal healthPrevalenceNeurological disorders; Global Burden of DiseasesCauses of deathPublic healthMortality rateMental DisordersAge FactorsPublic Health Global Health Social Medicine and EpidemiologyMiddle Agedneurologic diseaseDeathLýðheilsaFemaleLife Sciences & BiomedicineQuality of lifeAdultPopulationClinical NeurologySex FactorsmedicineLife ScienceDisability-adjusted life year:Medicine [Science]MortalityPsychiatryDisease burdenNeurology & Neurosurgeryburden of neurological disordersFaraldsfræðibusiness.industryKlinisk medicinCauses de la mort1103 Clinical SciencesFolkhälsovetenskap global hälsa socialmedicin och epidemiologiSocioeconomic FactorsKarlarglobal disease burdenNervous System DiseasesCause of death/trendsbusiness
researchProduct

Liraglutide and Renal Outcomes in Type 2 Diabetes.

2017

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a co…

MaleSettore MED/09 - Medicina InternaAcute Kidney Injury; Aged; Albuminuria; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kidney Failure Chronic; Liraglutide; Male; Middle AgedType 2 diabetes030204 cardiovascular system & hematologyurologic and male genital diseasesGLOMERULAR-FILTRATION-RATEKIDNEY-FUNCTIONDISEASElaw.inventionKidney Failurechemistry.chemical_compound0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawMedicineDiabetic NephropathiesHypoglycemic Agents.Settore MED/49 - Scienze Tecniche Dietetiche ApplicateChronicRISKKidneyAcute kidney injury11 Medical And Health SciencesGeneral MedicineAcute Kidney InjuryMiddle AgedIntention to Treat Analysismedicine.anatomical_structureCreatinineTRIALFemaleliraglutide randomized controlled trial type 2 diabetes renal outcomesLife Sciences & BiomedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyRenal function030209 endocrinology & metabolismCARDIOVASCULAR OUTCOMESFollow-Up Studie03 medical and health sciencesMedicine General & InternalDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicineDiabetes MellitusAlbuminuriaHumansHypoglycemic AgentsIntensive care medicineAgedCreatinineScience & Technologybusiness.industryLiraglutideMORTALITYLiraglutidemedicine.diseaseINTENSIVE GLUCOSE CONTROLINDIVIDUALSDiabetes Mellitus Type 2chemistryDiabetic NephropathieKidney Failure ChronicLEADER Steering Committee and InvestigatorsbusinessFollow-Up Studies
researchProduct

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

Mapping child growth failure across low- and middle-income countries

2020

Childhood malnutrition is associated with high morbidity and mortality globally1. Undernourished children are more likely to experience cognitive, physical, and metabolic developmental impairments that can lead to later cardiovascular disease, reduced intellectual ability and school attainment, and reduced economic productivity in adulthood2. Child growth failure (CGF), expressed as stunting, wasting, and underweight in children under five years of age (0–59 months), is a specific subset of undernutrition characterized by insufficient height or weight against age-specific growth reference standards3–5. The prevalence of stunting, wasting, or underweight in children under five is the proport…

Time FactorsDevelopmental DisabilitiesPsychological interventionDistribution (economics)0302 clinical medicinerisk factors030212 general & internal medicineSigns and symptomsWastingChildrenLocal Burden of Disease Child Growth Failure Collaborators2. Zero hungerMultidisciplinaryUnder-five1. No povertyPublic Health Global Health Social Medicine and EpidemiologyA900 Others in Medicine and Dentistry3. Good healthMultidisciplinary SciencesGeographyChild PreschoolScience & Technology - Other TopicsHEALTHUnderweightmedicine.symptomsocial sciencesInfantsAFRICAmedicine.medical_specialtyGeneral Science & TechnologyRJDeveloping countryNutritional StatusWorld Health OrganizationChild Nutrition DisordersArticleSocial sciencesMalnutrició03 medical and health sciencesAGEEnvironmental healthmedicineMortalitatHumansMortalityDeveloping CountriesScience & Technologybusiness.industryPublic healthMORTALITYBody WeightMalnutritionInfant NewbornInfantChild growth failuremedicine.diseasesigns and symptomsMalnutritionFolkhälsovetenskap global hälsa socialmedicin och epidemiologiRisk factorsWEIGHTbusinessRA030217 neurology & neurosurgery
researchProduct

Production of [Formula: see text] and [Formula: see text] in proton-proton collisions at [Formula: see text] 7 TeV.

2014

The production of the strange and double-strange baryon resonances (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\Sigma (1385)^{\pm }$$\end{document}Σ(1385)±, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\Xi (1530)^{0}$$\end{document}Ξ(1530)0) has been measured at mid-rapidity (\documentclass[12pt]{minimal} \usepackage{amsmath}…

Regular Article - Experimental Physics
researchProduct